Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable or Metastatic Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06265025
What this trial is testing

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Who this might be right for
Head and Neck CancerMalignant MelanomaColorectal Cancer+3 more
GeneMedicine Co., Ltd. 125
Testing effectiveness (Phase 2)Looking for participantsNCT05267626
What this trial is testing

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more
Aulos Bioscience, Inc. 159
Large-scale testing (Phase 3)Active Not RecruitingNCT06054555
What this trial is testing

Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma
Amgen 633
Testing effectiveness (Phase 2)Ended earlyNCT04032704
What this trial is testing

Ladiratuzumab Vedotin in Advanced Solid Tumors

Who this might be right for
Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
Seagen Inc. 205
Testing effectiveness (Phase 2)UnknownNCT03913923
What this trial is testing

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Who this might be right for
MelanomaMelanoma Metastatic
Biocad 117
Testing effectiveness (Phase 2)Study completedNCT04382664
What this trial is testing

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Who this might be right for
Malignant Melanoma
Ultimovacs ASA 156
Large-scale testing (Phase 3)Study completedNCT01844505
What this trial is testing

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Who this might be right for
Unresectable or Metastatic Melanoma
Bristol-Myers Squibb 945
Large-scale testing (Phase 3)Study completedNCT02905266
What this trial is testing

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 106
Early research (Phase 1)Study completedNCT02595866
What this trial is testing

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Who this might be right for
AIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more
National Cancer Institute (NCI) 58
Early research (Phase 1)Study completedNCT04640545
What this trial is testing

Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Who this might be right for
Advanced Melanoma
Nanjing Leads Biolabs Co.,Ltd 79
Testing effectiveness (Phase 2)Study completedNCT05419388
What this trial is testing

Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma
Hoffmann-La Roche 93
Large-scale testing (Phase 3)Study completedNCT03635983
What this trial is testing

NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 783
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Early research (Phase 1)Study completedNCT01245556
What this trial is testing

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 8
Testing effectiveness (Phase 2)Ended earlyNCT02314143
What this trial is testing

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Who this might be right for
Melanoma
GlaxoSmithKline 48
Post-approval studies (Phase 4)Active Not RecruitingNCT02068196
What this trial is testing

A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.

Who this might be right for
Malignant Melanoma
Oslo University Hospital 150
Early research (Phase 1)Study completedNCT00089362
What this trial is testing

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Who this might be right for
Male Breast CancerRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Basal Cell Carcinoma of the Lip+73 more
National Cancer Institute (NCI) 30
Large-scale testing (Phase 3)Active Not RecruitingNCT02339571
What this trial is testing

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Who this might be right for
Stage III Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
National Cancer Institute (NCI) 600
Early research (Phase 1)Study completedNCT01673737
What this trial is testing

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

Who this might be right for
Neoplasm Malignant
Sanofi 75
Testing effectiveness (Phase 2)Ended earlyNCT04768881
What this trial is testing

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Who this might be right for
Locally Advanced Unresectable or Metastatic Melanoma
Karyopharm Therapeutics Inc 15
Next Page